NBI Development

Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, specializing in the discovery and development of treatments for neurological, endocrine, and psychiatric disorders. The company is best known for its flagship product, INGREZZA (valbenazine), the first FDA-approved treatment for tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine also co-developed ORILISSA (elagolix) for endometriosis and ORIAHNN for uterine fibroids in partnership with AbbVie. With a robust pipeline including crinecerfont for congenital adrenal hyperplasia and several muscarinic agonists for schizophrenia, the company leverages small molecule and genetic medicine platforms to address significant unmet medical needs. Headquartered in San Diego, Neurocrine has established itself as a major player in the CNS space through strategic partnerships and internal R&D excellence.